<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>and therapeutic implications &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/and-therapeutic-implications/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sun, 25 Jan 2026 11:21:14 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>and therapeutic implications &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Inhibiting ITGB2 Axis Suppresses Melanoma Growth</title>
		<link>https://bioengineer.org/inhibiting-itgb2-axis-suppresses-melanoma-growth/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 25 Jan 2026 11:20:44 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[and therapeutic implications]]></category>
		<category><![CDATA[Based on the content highlighting ITGB2's role in melanoma progression]]></category>
		<category><![CDATA[Cancer therapeutics** * **ITGB2 inhibition:** Ana araştırma konusu ve terapötik hedef. * **Melanoma targeted therapy:** Çalışmanın odaklandığı hastalık (melanoma) ve tedavi yaklaşımı (he]]></category>
		<category><![CDATA[drug resistance]]></category>
		<category><![CDATA[here are 5 appropriate tags: **Melanoma Therapy]]></category>
		<category><![CDATA[İçerik analizi sonucunda en uygun 5 etiket: **ITGB2 inhibition]]></category>
		<category><![CDATA[inhibition strategies]]></category>
		<category><![CDATA[ITGB2 Inhibition]]></category>
		<category><![CDATA[Melanoma drug resistance]]></category>
		<category><![CDATA[Melanoma targeted therapy]]></category>
		<category><![CDATA[Metastasis]]></category>
		<category><![CDATA[microenvironment interactions]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/inhibiting-itgb2-axis-suppresses-melanoma-growth/</guid>

					<description><![CDATA[Recent research has unveiled a crucial pathway in melanoma progression, identifying the tumor cell-intrinsic ITGB2 axis as a promising target for therapeutic intervention. This groundbreaking study, led by Rasbach et al., emphasizes the importance of exploring intrinsic cellular mechanisms to combat one of the most aggressive forms of skin cancer. The team discovered that melanoma [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">320679</post-id>	</item>
		<item>
		<title>HDAC1 Condensation Links to Temozolomide Response in Glioblastoma</title>
		<link>https://bioengineer.org/hdac1-condensation-links-to-temozolomide-response-in-glioblastoma/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 10 Jan 2026 11:32:21 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[and therapeutic implications]]></category>
		<category><![CDATA[Based on the content focusing on the molecular mechanism of temozolomide resistance involving HDAC1 condensation]]></category>
		<category><![CDATA[HDAC1 condensation]]></category>
		<category><![CDATA[here are 5 appropriate tags: **Glioblastoma]]></category>
		<category><![CDATA[phase separation]]></category>
		<category><![CDATA[Targeted therapy** **Reasoning:** 1. **Glioblastoma:** The primary cancer type studied. 2. **Temozolomide resistance:** The core clinical problem being addressed. 3. **]]></category>
		<category><![CDATA[Temozolomide Resistance]]></category>
		<guid isPermaLink="false">https://bioengineer.org/hdac1-condensation-links-to-temozolomide-response-in-glioblastoma/</guid>

					<description><![CDATA[In the ongoing battle against glioblastoma, one of the most aggressive forms of brain cancer, the standard therapy temozolomide has been a beacon of hope. However, this hope is often tempered by the unfortunate reality that patients who initially respond well to the drug may later experience a significant decline in its efficacy. This phenomenon, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">315645</post-id>	</item>
	</channel>
</rss>
